Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05694936 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started2023-01-23
View on ClinicalTrials.gov ↗
The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC.

Amendment record

Amended 5 times since 2023-01-19; most recent filed 2026-05-05. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-05-05
Amendment Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v5
2025-09-12
Amendment Study Identification, Study Status v4
2025-07-27
Amendment Study Status, Contacts/Locations v3
2023-11-01
Amendment Study Status, Contacts/Locations v2
2023-01-22
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
2023-01-19
Original filing
Trial Details
NCT Number NCT05694936
Lead Sponsor Australasian Gastro-Intestinal Trials Group
Collaborators: Olivia Newton-John Cancer Research Institute
Conditions Metastatic Colorectal Cancer
Enrollment 38 participants
Start Date 2023-01-23
Primary Completion 2026-01-21 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-08